Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial
Autor: | Robertson, John FR, Ferrero, Jean-Marc, Bourgeois, Hugues, Kennecke, Hagen, de Boer, Richard H, Jacot, William, McGreivy, Jesse, Suzuki, Samuel, Zhu, Min, McCaffery, Ian, Loh, Elwyn, Gansert, Jennifer L, Kaufman, Peter A |
---|---|
Zdroj: | In Lancet Oncology March 2013 14(3):228-235 |
Databáze: | ScienceDirect |
Externí odkaz: |